iCo Therapeutics iCo Therapeutics Inc.

  • Home
  • Corporate Overview
    • Overview
    • Partnering Strategy
    • Management Team
    • Board of Directors
    • Strategic Advisory Board
    • Professional Advisors
  • Pipeline
    • iCo-007
    • Antisense Technology
    • iCo-008
    • iCo-009
    • Clinical Trials
  • Investor Relations
    • Overview
    • Press Releases
    • Media Coverage
    • Upcoming Events
  • Careers
    • About Vancouver
    • Current Opportunities
  • Contact Us

Investor Relations

Press Release

iCo Therapeutics Elects Dr. Richard W. Barker and William Jarosz as Independent Directors

June 5, 2006

Vancouver, CANADA – iCo Therapeutics announced today the appointment of Dr. Richard W. Barker and William Jarosz to its board of directors.

Dr. Barker is currently Director General of the Association of the British Pharmaceutical Industry (ABPI). His twenty years of experience includes a number of senior leadership roles in the UK and abroad and spans the pharmaceutical, biotechnology and medical informatics sectors.

William Jarosz is currently a Partner in the global investment management firm Cartesian Capital Group, LLC. He has broad expertise in international private equity investments, cross-border acquisitions, capital markets, and corporate and securities laws.

“We are thrilled to have both Dr. Barker and Mr. Jarosz join the iCoTherapeutics team,” said company President and CEO Andrew Rae. “Their membership on our board adds strategic expertise in numerous capacities including both the clinical and business aspects of drug development.”

Prior to joining the ABPI, Dr. Barker was founder and president of New Medicine Partners, a consulting firm to pharmaceutical and biotech enterprises. His past roles include CEO of iKnowMed, a clinical decision support and pharmaceutical services business in oncology; Chief Executive of Chiron Diagnostics, General Manager of IBM’s Worldwide Healthcare Solutions division, and leader of McKinsey’s European healthcare practice.

“iCoTherapeutics’ strategic approach to drug development and commercialization is novel and sound,” said Dr. Barker. “I look forward to working with the entire iCo team to provide a global perspective towards helping bring promising new opportunities to the treatment of eye diseases.”

Dr. Barker is currently a board member of the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA) and council member of the international equivalent body (IFPMA). He serves on the board of Adlyfe, a company specializing in protein misfolding diseases. Dr. Barker holds a D. Phil in biophysics and a BA in chemistry both from Oxford University. His research is in biological magnetic resonance at Oxford, Leeds and Munich.

Prior to helping found Cartesian Capital Group, LLC, Mr. Jarosz served as Managing Director and General Counsel of AIG Capital Partners, a subsidiary of American International Group, Inc., and as Managing Director of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr. Jarosz was responsible for various private equity transactions for the firm’s global private equity funds.

Mr.Jarosz practiced law at Debevoise & Plimpton, specializing in international private equity investment and general corporate and securities transactions. He also served as a consultant to the World Bank on the regulation of Foreign Direct Investment in emerging markets. Mr. Jarosz is a graduate of the University of Montana, and received an MA in Law and Diplomacy from the Fletcher School at Tufts University and a JD from Harvard Law School.

About iCo Therapeutics Inc.

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, a oral reformulation of Amphotericin B for sight and life – threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenterally administered drugs to the oral route of administration.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol “ICO”.

No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Business Development Contact:
Dr. John Clement, CBO
604.602.9414 × 222

Finance Contact:
Mr. John Meekison, CFO
604.602.9414 × 224

Investor Contact:
Frederica Bell, Director, Corporate Development
604.602.9414 × 228

image

Investor & Media Contact

Frederica Bell, BSc, MBA
Director of Corporate Development
604.602.9414 office
778.385.2549 cell

Contact Us

Items with an asterisk * are required






  • Home
  • Corporate Overview
  • Pipeline
  • Investor Relations
  • Careers
  • Contact Us

Copyright © 2005 iCo Therapeutics Inc. All rights reserved. Terms of Use.